Context Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 5
- Market Cap
- $187.4M
- Introduction
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone exten...
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
BioAtla reported Q3 2024 financial results and clinical progress, including ozuriftamab vedotin Phase 2 trial in head and neck cancer showing 9-month median overall survival, and evalstotug demonstrating tumor reduction in melanoma patients. The company received FDA guidance for potential registrational trials in 2025. Q3 net loss was $10.6M, with revenue of $11.0M from a licensing agreement. R&D expenses decreased to $16.4M from $28.4M year-over-year. Cash position of $56.5M is expected to fund operations into early 2026.
Related Clinical Trials:
BioAtla to Score Up to $133M
BioAtla, a global clinical-stage biotech, struck a deal with Context Therapeutics for the acquisition of its cancer-fighting drug BA3362, with potential payments up to $133 million. The drug, based on BioAtla's Conditionally Active Biologics (CAB) platform, aims to reduce toxicities and increase anti-tumor potency. Context will fund future development and commercialization activities, with BA3362 expected to enter human trials in about a year and a half.
© Copyright 2024. All Rights Reserved by MedPath